SWITCHING BETWEEN CALCITONIN GENE RELATED PEPTIDE MONOCLONAL ANTIBODIES IN THE PROPHYLAXIS OF MIGRAINE

M.R. CANTUDO CUENCA, M.I. ARCHILLA AMAT, M. ARENAS JIMENEZ, A.Y. SALMERON COBOS, A. JIMENEZ MORALES

HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES, PHARMACY, GRANADA, SPAIN

BACKGROUND AND IMPORTANCE

Therapeutic options for migraine prevention in non-responders patients to monoclonal antibodies (mAbs) targeting Calcitonin Gene-Related Peptide (CGRP) and its receptor are often limited. **There is no recommendations of switching between mAbs classes**.

AIM AND OBJECTIVE

To assess the **effectiveness and safety** of mAb switching in non-responders migraine patients.

METHODS AND MATERIAL

Retrospective observational study in a tertiary hospital (1-January-2021 to 31-July-2023).

Monthly headache days (MHD) were collected to assess the ≥50% responder rates and **the absolute reduction of MHD at 3 months,** as well as, **the absolute reduction of monthly acute medication days (AMD).**

We **included** patients who received a first mAb for ≥3 months, were non- responders and switched to another mAb class.

Patients were **excluded** if they switched due to side effects.

Data were recorded from electronic medical records and patients interviews. The study was approved by the Ethics Committee. Informed consent was obtained.

RESULTS

First mAb

110 patients galcanezumab (n=57) fremanezumab (n=53)

24 (21,8%) switched to the CGRP-receptor mAb

105 patients erenumab

30 (28,6%) switched to a CGRP-ligand mAb

	Switched from ligand mAb to receptor mAb (n=23)	Switched from receptor mAb to ligand mAb (n=28)
Female, n(%)	21 (91,3)	27 (96,4)
Age in years, mean(SD)	44,9 (11)	46,5 (12,6)
Disease duration in years, median(IQR)	13 (8,3-18,5)	12 (8-23,3)
Diagnosis, n(%) High-frequency episodic migraine Chronic migraine	 2 (8,7) 21 (91,3)	 10 (35,7) 18 (64,3)
Aura, n(%)	2 (8,7)	4 (14,3)
Comorbidities, n(%) Anxious-depressive syndrome Fibromyalgia	 4 (17,4) 2 (8,7)	 10 (35,7) 1 (3,6)
Concomitant prophylaxis, n(%)	8 (34,8)	13 (46,4)
Treatment duration in months, median(IQR)	5 (3,75-7)	9 (5-11)

The **≥50% responder rate was 40%** and **61,9% at 3 months** with erenumab and CGRP-ligand mAb, respectively.

MHD reduction: 17±7,4 to 13,8±8,7 and 16±7,7 to 8,4±6,1, respectively. **AMD reduction:** 16,1±9,9 to 15,4±10,2 and 11,7±9,2 to 7,6±7,3

Seven patients (35%) changed to a third mAb in patients that switched from ligand mAb to receptor mAb, 23,8% in the other group.

CONCLUSIONS AND RELEVANCE

Switching seems to be a promising treatment option especially in migraine patients that switched from CGRP-receptor mAb to CGRP-ligand mAb. However, some of them need to switch to a third mAb. More studies are needed to describe which patients will respond to CGRP-mAb switching.